Fortrea Holdings Inc. (FTRE)
FTRENASDAQ-GSMedical Specialities
$20.11
-1.55 (-7.16%) today
Closed, Nov 11, 4:00 PM ET
- Market cap
- $1.97bn
- P/E
- 26.5
- EPS, last 4 quarters
- $0.7600
- Dividend yield
- –
- Day range
- –
- 52-week range
- $8.55 to $26.16
- Average volume
- –
- Previous close
- $21.66
Analysts
10 coveringHold7 buy, 2 hold, 1 sell
Targets a year out average $25.13, +25.0% from here
Earnings
next estimate $0.1900Next report
Dec 2025
-43.8%
Mar 2026
+433.3%
Jun 2026
+27.8%
Sep 2026
+16.7%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $660.50m | $636.50m | $678.20m | $691.50m |
| Gross profit | $131.10m | $123.60m | $139.20m | $139.50m |
| Operating income | -$13.60m | -$3.40m | $14.80m | $15.00m |
| Net income | -$32.50m | -$23.60m | -$13.20m | $600.0k |
Last four quarters: revenue $2.67bn, margin -2.6%, free cash flow $169.00m
News
8 latest- Fortrea (FTRE) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 29, 2026
- What Fortrea (FTRE) Said on Its Q3 Earnings CallMarketBeat · Oct 29, 2026
- Fortrea Holdings Inc. Reports Third Quarter 2026 Financial Results and Updates Full-Year GuidanceFintel · Oct 29, 2026
- Fortrea Holdings Inc. (FTRE) Q3 Earnings and Revenues Surpass EstimatesZacks · Oct 29, 2026
- Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?Zacks · Oct 26, 2026
- Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?Zacks · Oct 22, 2026
- Fortrea Completes $45 Mln Acquisition Of Worldwide's Early Phase Services Divisions RTTNews · Oct 20, 2026
- Biotech Stocks At 52-Week Highs - PACB, FTRE, ALMR, TXG, AZTA RTTNews · Oct 7, 2026
The company
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services, delivered in highly flexible models that include full service, functional service provider and hybrid service structures. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, technology innovation and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to clients globally.
- Sector
- Health Care
- Industry
- Medical Specialities
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- fortrea.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.